Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050070990 A1
Publication typeApplication
Application numberUS 10/672,891
Publication dateMar 31, 2005
Filing dateSep 26, 2003
Priority dateSep 26, 2003
Also published asCA2539491A1, EP1663071A2, EP1663071B1, US8137614, US20100228334, US20120150276, WO2005030095A2, WO2005030095A3
Publication number10672891, 672891, US 2005/0070990 A1, US 2005/070990 A1, US 20050070990 A1, US 20050070990A1, US 2005070990 A1, US 2005070990A1, US-A1-20050070990, US-A1-2005070990, US2005/0070990A1, US2005/070990A1, US20050070990 A1, US20050070990A1, US2005070990 A1, US2005070990A1
InventorsJonathan Stinson
Original AssigneeStinson Jonathan S.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Medical devices and methods of making same
US 20050070990 A1
Abstract
Medical devices, such as stents, and methods of the devices are described.
Images(9)
Previous page
Next page
Claims(40)
1. A balloon-expandable medical stent, comprising:
a generally tubular body including an alloy having Ti at about 20 weight percent or more and at least one of Zr, Ta, or Mo, the alloy having a yield strength of about 45 ksi or more, a magnetic susceptibility of about +1 or less, and a mass absorption coefficient of about 1.9 cm2/g or more.
2. The stent of claim 1 wherein the alloy has a UTS of about 90 ksi or more and the percent tensile elongation is about 40 or more.
3. The stent of claim 1 wherein the yield strength is about 50 ksi or greater, the percent strength to peak load is about 30 or greater, the UTS is about 90 ksi or greater, and the percent strength to fracture is about 40 or greater.
4. The stent of claim 1 wherein the magnetic susceptibility is about 3.5×10−3 or less.
5. The stent of claim 1 wherein the mass absorption coefficient is about 2.9 cm2/g or less.
6. The stent of claim 1 wherein the alloy includes about 50 weight percent Ti or greater.
7. The stent of claim 1 wherein the alloy includes 20 weight percent or greater of Zr, Ta or Mo or a combination thereof.
8. The stent of claim 1 wherein the alloy includes 80 weight percent or less of Zr, Ta or Mo or a combination thereof.
9. The stent of claim 1 wherein the alloy includes 10 weight percent or more of Zr.
10. The stent of claim 1 wherein the alloy includes about 50 weight percent of Zr.
11. The stent of claim 1 wherein the alloy includes about 40 weight percent or more of Ta.
12. The stent of claim 1 wherein the alloy includes about 75 weight percent or less of Ta.
13. The stent of claim 1 wherein the alloy includes about 3 weight percent or more of Mo.
14. The stent of claim 1 wherein the alloy includes about 20 weight percent or less of Mo.
15. The stent of claim 1 wherein the alloy is Ti-Ta, Ti-Mo, Ti-Zr, Ti-Ta-Mo, Ti-Ta-Zr, Ti-Ta-Zr-Mo, Ti-Zr-Mo, Ti 6A1-4V-Ta, Ti 6A1-4V-Mo, Ti 6A1-4V-Zr, Ti 6A1-4V-Ta-Mo, Ti 6A1-4V-Ta-Zr, Ti 6A1-4V-Ta-Zr-Mo, Ti 6A1-4V-Zr-Mo, Ti-13Nb-13Zr, Ti-13Nb-13Zr-Mo, Ti-13Nb-13Zr-Ta, Ti-8A1-1Mo-1V, Ti-8A1-1Mo-1V-Zr, Ti-8A1-1Mo-1V-Ta, Ti-6A1-2Nb-1Ta-0.8Mo, or Ti-6A1-2Nb-0.8Mo-Zr.
16. The stent of claim 1 wherein the alloy of CP titanium, Ti-6A1-4V, or Ti-6A1-4V ELI alloyed with 40 to 70 weight percent of Ta or 25 to 50 weight percent of Zr.
17. The stent of claim 16 where the alloy includes 5 to 20 weight percent of Mo.
18. The stent of claim 1 wherein the alloy is selected from:
CP Titanium alloyed with: Ti—6Al—4V ELI alloyed with: 43 weight % Ta 43 weight % Ta 69 weight % Ta 69 weight % Ta 25 weight % Ta 25 weight % Ta 49 weight % Zr 49 weight % Zr 43 weight % Ta + 5% Mo 43 weight % Ta + 5% Mo 69 weight % Ta + 5% Mo 69 weight % Ta + 5% Mo 25 weight % Zr + 5% Mo 25 weight % Zr + 5% Mo 49 weight % Zr + 5% Mo 49 weight % Zr + 5% Mo 43 weight % Ta + 10% Mo 43 weight % Ta + 10% Mo 69 weight % Ta + 10% Mo 69 weight % Ta + 10% Mo 25 weight % Zr + 10% Mo 25 weight % Zr + 10% Mo 49 weight % Zr + 10% Mo 49 weight % Zr + 10% Mo 22 weight % Ta + 13% Mo 22 weight % Ta + 13% Mo 35 weight % Ta + 25% Mo 35 weight % Ta + 25% Mo
19. The stent of claim 1 wherein the tubular body includes wall portions having a thickness of about 0.0015 inch to about 0.0150 inch.
20. The stent of claim 1 wherein the tubular body includes a therapeutic agent.
21. A system including a catheter for delivery into a body lumen, the catheter including an expandable member and a stent as described in claim 1 disposable over the expandable member, the expandable member expandable to a maximum diameter of about 1.5 mm to about 14 mm.
22. An implantable medical device, comprising:
an alloy having Ti at about 20 weight percent or more and at least one of Zr, Ta, or Mo, the alloy having a yield strength of about 45 ksi or more, a magnetic susceptibility of about +1 or less, and a mass absorption coefficient of about 1.9 cm2/g or more, the medical device selected from a filter, a guidewire, a catheter, a needle, a biopsy needle, a staple, and a cannula.
23. A method of forming a stent, comprising:
providing an alloy including Ti of about 20 weight percent or more and at least one additive selected from the group consisting of Zr, Ta and Mo by:
contacting solid aliquots of a titanium component selected from Ti or a Ti-containing alloy, and the additive,
heating the aliquot after the contacting,
mechanically working the aliquots after contacting by forging, extrusion, drawing or rolling,
melting the aliquots,
forming a first mass,
forming a tube including the alloy, and
incorporating the tube into a stent.
24. The method of claim 23 wherein the contacting includes providing a body composed of the titanium component or the additive including voids and inserting into the voids the additive or titanium component.
25. The method of claim 24 wherein the body is a rod and the voids are lumens in the rod.
26. The method of claim 25 wherein the lumens are elongate lumens substantially arranged along the axis of the rod.
27. The method of any one of claims 24 and 26 wherein the body is formed of the titanium component.
28. The method of claim 27 wherein the additive is the form of a particulate or a solid wire.
29. The method of claim 23 wherein the heating includes causing diffusion between the titanium component and the additive.
30. The method of claim 29 comprising heating to a temperature within ±10% of the melting point of the titanium component.
31. The method of claim 23 comprising heating after the mechanical working.
32. The method of claim 23 comprising:
after forming the first mass, contacting the first mass with further additive, melting the first mass in contact with the further aliquot, and forming a second mass having a greater amount of additive.
33. The method of claim 32 comprising mechanically working or heating the first mass in contact with the further aliquot, prior to melting.
34. The method of claims 23 comprising:
melting by vacuum arc remelting, electron beam, plasma or vacuum induction melting.
35. The method of claim 23 comprising forming the first mass having a volume of about 6.5 in3 or less.
36. The method of claim 35 where the first mass is in the form of a cylinder.
37. The method of claim 23 wherein forming the tube includes forming a tube from the first mass by drawing or sheet-rolling.
38. The method of claim 23 wherein incorporating the tube into a stent includes machining the tube to include apertures in the wall of the tube.
39. The method of claim 23 wherein the stent is a vascular, balloon-expandable stent.
40. A method of forming a medical device, comprising:
providing a metal alloy of multiple components of elements or alloys, including a first component and a second component having a melting point difference of about 150° C. or more by contacting solid aliquots of the first component and the second component,
heating and/or mechanically working the aliquots after contacting to form a first mass,
melting the first mass,
forming a second mass from the first mass, and
incorporating the alloy into a medical device.
Description
    TECHNICAL FIELD
  • [0001]
    The invention relates to medical devices, such as, for example, stents and stent-grafts, and methods of making the devices.
  • BACKGROUND
  • [0002]
    The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents and covered stents, sometimes called “stent-grafts”.
  • [0003]
    An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • [0004]
    When the endoprosthesis is advanced through the body, its progress can be monitored, e.g., tracked, so that the endoprosthesis can be delivered properly to a target site. After the endoprosthesis is delivered to the target site, the endoprosthesis can be monitored to determine whether it has been placed properly and/or is functioning properly.
  • [0005]
    Monitoring of the position of the endoprosthesis during implantation is typically performed by a radiographic technique such as fluoroscopy. The radiographic density of the metal endoprosthesis is different from bone and tissue, and the device is observed in the fluoroscopic image from the visible difference in contrast and grey scale relative to the surrounding biological material. The disadvantage of fluoroscopy is that the physician, staff, and patient are exposed to ionizing radiation which can be harmful in strong or repeated doses.
  • [0006]
    Another method of monitoring a medical device is magnetic resonance imaging (MRI). MRI uses a magnetic field and radio waves to image the body. In some MRI procedures, the patient is exposed to a magnetic field, which interacts with certain atoms, e.g., hydrogen atoms, in the patient's body. Incident radio waves are then directed at the patient. The incident radio waves interact with atoms in the patient's body, and produce characteristic return radio waves. The return radio waves are detected by a scanner and processed by a computer to generate an image of the body.
  • SUMMARY
  • [0007]
    In an aspect, the invention features a balloon-expandable medical stent. The stent includes a generally tubular body including an alloy having Ti at about 20 weight percent or more and at least one of Zr, Ta, or Mo. The alloy has a yield strength of about 45 ksi or more, a magnetic susceptibility of about +1 or less, and a mass absorption coefficient of about 1.9 cm2/g or more.
  • [0008]
    In another aspect, the invention features a system including a catheter for delivery into a body lumen. The catheter includes an expandable member and a stent as described herein disposable over the expandable member. The expandable member is expandable to a maximum diameter of about 1.55 mm to about 14 mm.
  • [0009]
    In another aspect, the invention features an implantable medical device including an alloy having Ti at about 20 weight percent or more and at least one of Zr, Ta, or Mo, a yield strength of about 45 ksi or more, a magnetic susceptibility of about +1 or less, and a mass absorption coefficient of about 1.9 cm2/g or more. The medical device can be a filter, a guidewire, a catheter, a needle, a biopsy needle, a staple, or a cannula.
  • [0010]
    In another aspect, the invention features a method of forming a stent. The method includes providing an alloy including Ti of about 20 weight percent or more and at least one of an additive selected from Zr, Ta or Mo. The method includes contacting solid aliquots of a titanium component selected from Ti or a Ti-containing alloy, and the additive heating the aliquot after the contacting, and mechanically working the aliquots after contacting by forging, extrusion, drawing or rolling, melting the aliquots, forming an ingot, forming a tube including the alloy, and incorporating the tube into a stent.
  • [0011]
    In an aspect, the invention features a method of forming a medical device. The method includes providing a metal alloy of multiple components of elements or alloys, including a first component and a second component having a melting point difference of about 150° C. or more. Solid aliquots of the first component and the second component are contacted, heated and/or mechanically worked, then the worked components are melted. The alloy is incorporated into a medical device.
  • [0012]
    In another aspect, the invention features a medical device including an alloy that exhibits one or more (e.g., two, three, or four) properties selected from radiopacity, MRI capability, mechanical properties, and/or biocompatibility properties as described herein, in any combination. In other aspects, the invention features particular alloys and techniques for making the alloys.
  • [0013]
    In yet another aspect, the invention features a medical device including a titanium alloy having at least one of zirconium, tantalum, molybdenum, or niobium. The alloy exhibits radiopacity, MRI capability, mechanical properties, and/or biocompatibility properties, and combinations of the properties as described herein. In other aspects, the invention features particular alloys and techniques for making the alloys.
  • [0014]
    Embodiments may include one or more of the following advantages. A stent or other medical device is provided that includes desirable magnetic imaging radiopacity, biocompatibility and/or mechanical characteristics. For example, the stent is less susceptible to magnetic resonance image degradation (e.g., less than stainless steel) Implant movement or heating can be reduced. The stent alloy has sufficient radiopacity that the stent is visible by fluoroscopy. The mechanical characteristics of the alloy enable a stent of conventional design that can be delivered into the body in a reduced diameter configuration and then expanded at a treatment site, e.g., by a balloon catheter. The titanium alloys generally can exhibit enhanced strength, stiffness and radiopacity, while maintaining low magnetic susceptibility.
  • [0015]
    Still further aspects, features, and advantages follow.
  • DESCRIPTION OF DRAWINGS
  • [0016]
    FIGS. 1A and 1B are perspective views of a stent in a compressed and expanded condition, respectively.
  • [0017]
    FIGS. 2A-2C illustrate delivery of a balloon expandable stent.
  • [0018]
    FIG. 3 is a flow diagram of a stent manufacturing process.
  • [0019]
    FIGS. 4A-4F illustrate a process for making a medical device.
  • [0020]
    FIGS. 5-8 are photo micrographs.
  • DETAILED DESCRIPTION
  • [0021]
    • Structure and Alloy Formulation
  • [0022]
    Referring to FIGS. 1A and 1B, a stent 10 includes a metal body 12 in the shape of a tube. The metal body includes aperture regions 14 provided in a pattern to facilitate stent functions, such as radial expansion, and lateral flexibility. Between aperture regions are strut regions 16. Referring particularly to FIG 1A, for delivery into the body, the stent 10 is provided or maintained in a relatively small diameter condition corresponding to a diameter Dc. Referring to FIG 1B, upon placement at the treatment site, the stent 10 is expanded to a larger diameter, Dexp, so that the stent is in contact with the lumen wall. The stent may be expanded by a mechanical expander, such as an inflatable balloon, or it may be self-expanding. The metal body of the stent may be formed by a generally continuous sheet or by filaments that are wrapped, braided, knitted or otherwise configured to generally define a stent.
  • [0023]
    Referring now to FIGS. 2A-2C, the delivery of a balloon-expandable stent is illustrated. The stent 300 is carried on a catheter 302 over a balloon 304. When the treatment site is reached, the balloon is expanded to expand the stent into contact with the lumen wall. The stent may be used in the vascular system (e.g., in the coronary or peripheral arteries), or in other body lumens.
  • [0024]
    The stent body is formed of a metal alloy that has desirable magnetic resonance, radiopacity, biocompatibility, and/or mechanical characteristics. In embodiments, the alloy is a titanium-containing alloy that includes one or more of Zr, Ta or Mo. In particular embodiments, the alloy is formed from commercially pure (CP) titanium or Ti-6A1-4V ELI, which has been alloyed with one or more of Zr, Ta, or Mo by processes that include mechanical or diffusion alloying followed by melting, as will be described below.
  • [0025]
    The alloy is formulated to provide desired characteristics. For MRI compatibility, the alloy is formulated to reduce signal distortion, electrical current (e.g., eddy current) generation, heating, movement within the body or nerve simulation, by controlling the magnetic susceptibility and solubility of the alloy constituents. The magnetic susceptibilities of Ti, Zr, Ta, and Mo and other materials are provided in Table I.
    TABLE I
    Magnetic Susceptibilities
    Material: Magnetic Susceptibility:
    Water at 37° C. −9.05 × 10−6
    Human tissues −11.0 × 10−6 to −7.0 × 10−6
    copper −9.63 × 10−6
    ferromagnetic iron +105
    magnetic stainless steel (martensitic) +103
    stainless steel (austenitic) +3.5 × 10−3 to +6.7 × 10−3
    heavily cold worked stainless steel +1 to +10
    (austenitic)
    Nitinol (Ni—Ti) +0.245 × 10−3
    zirconium +0.109 × 10−3
    titanium +0.182 × 10−3
    niobium +0.237 × 10−3
    platinum +0.279 × 10−3
    molybdenum +0.123 × 10−3
    tantalum +0.178 × 10−3
  • [0026]
    In embodiments, the magnetic susceptibility of the alloy is less than the magnetic susceptibility of austenitic stainless steel, e.g. about +1 or less or about 3.5×10−3 or less. Solubility of the constituents can be determined by binary phase diagrams. Suitable solubility is indicated by a single phase (alpha or beta) or by a two phase solution (alpha and beta) at room temperature. Examples of suitable phase diagrams are available in the ASM Handbook, volume 3, ASM International, 1992, the entire contents of which is hereby incorporated by reference.
  • [0027]
    For radiopacity, the alloy is formulated to a desired mass absorption coefficient. Preferably, the stent is readily visible by fluoroscopy, but does not appear so bright that detail in the fluoroscopic image is distorted. In some embodiments, the alloy or the device has a radiopacity of from about 1.10 to about 3.50 times (e.g., greater than or equal to about 1.1, 1.5, 2.0, 2.5, or 3.0 times; and/or less than or equal to about 3.5, 3.0, 2.5, 2.0, or 1.5 times) that of 316L grade stainless steel, as measured by ASTM F640 (Standard Test Methods for Radiopacity of Plastics for Medical Use). Mass absorption coefficients and densities or Ti, Ta, Zr and Mo are compared to 316L stainless steel in Table II.
    TABLE II
    Mass Absorption Coefficients
    Alloy
    316L SS Ti Ta Zr Mo
    Mass absorption 1.96 (Fe) 1.21 5.72 6.17 7.04
    coefficient, cm2/g
    Density, g/cc 8.0 4.5 16.7 6.5 10.2
  • [0028]
    In embodiments, the mass absorption coefficient of the alloy is about 1.96 cm2/g (corresponding substantially to the mass absorption coefficient of Fe) to about 2.61 cm2/g (corresponding to about 0.5 the mass absorption coefficient of Ta). Mass absorption coefficient can be calculated from the results of radiopacity tests, as described in The Physics of Radiology, H. E. Johns, J. R. Cunningham, Charles C. Thomas Publisher, 1983, Springfield, Ill., pp. 133-143. A calculation of alloy mass absorption coefficient is provided in the examples, infra.
  • [0029]
    For desirable mechanical properties, the alloy is formulated based on solubility and phase structure. In particular embodiments, the alloy exhibits certain mechanical properties within about ±20% (e.g., within about ±10%, about ±5%, or about ±1%) of the corresponding value for stainless steel. Mechanical properties for select materials are provided in Table III.
    TABLE III
    Mean Tensile Test Data (Annealed Condition)
    0.2% offset % strain UTS, % strain to E,
    Tubing Ys, ksi to peak load ksi fracture msi
    316L SS 50 36  94 45 29
    Tantalum 24 No data 35-70 40 27
    CP Titanium 25-70 No data 35-80 15-25 15
    Ti—6Al—4V 120  No data 130 15 17
    ELI
  • [0030]
    Yield strength (YS) relates to the applied pressure needed to flow the alloy to expand the stent. The percent strain to peak load indicates how far the material can strain before necking occurs. The ultimate tensile strength (UTS) is the stress value that corresponds with strain to peak load. The percent strain to fracture is a measure of how far the material can be stretched prior to break, and includes uniform deformation plus location deformation in the necked down region. This property relates to stent strut fracture from over-expansion of the stent. Suitable test methods for determining these parameters are described in ASTM E8 (Standard Test Methods for Tension Testing of Metallic Materials). In Table III, the 316L SS properties were measured from annealed stent tubing. The other material properties were taken from handbooks, such as American Society for Metals Handbook Desk Edition, H. E. Boyer, T. L. Gall, 1985.
  • [0031]
    The solubility of the constituents and phase structure of the alloy is indicated by phase diagrams. Suitable solubilities are indicated by alpha and/or beta microstructures without substantial amounts of more brittle phases such as alpha prime, alpha double prime or omega phases. Active rapid cooling after melting can be utilized to reduce precipitation of these phases. In embodiments, the presence of brittle phases is less than about 10% (e.g., less than about 7%, 5%, or 3%) as measured by X-ray diffraction analysis. The presence of two phases is preferably equal to or less than the amount in commercially available Ti-6A1-4V (available from Allegheny Technologies Allvac (Monroe, N.C.) or Metalmen Sales (Long Island City, N.Y.). Alloying Ti with Ta and Mo increases modulus of elasticity. Alloying Ti with Ta, Mo, and/or Zr increases tensile strength. In embodiments, tensile properties are balanced by annealing the alloy. For example, annealing time and temperature can be selected to produce a maximum level of ductility while meeting minimum design requirements for yield strength and grain size. Alternatively or in addition, the stent design can be modified to accommodate less favorable mechanical properties. For example, for a lower tensile elongation (% strain to fracture) the stent is designed to lower the strain on the struts during expansion, such as by increasing the number of deformation “hinge” points in the stent so that the total stent deformation is distributed in smaller amounts to the areas where deformation occurs.
  • [0032]
    Biocompatibility of the stent is provided by alloying biocompatible constituents or coating the sent with a biocompatible material. Biocompatibility can be tested by using industry standard ISO 10992 in-vitro and in vivo test methods, which can provide a qualitative pass or fail indication. In embodiments, the stent has a biocompatibility similar to or equivalent to pure titanium or pure tantalum, as measured by ISO 10992 test methods.
  • [0033]
    In embodiments, the alloy constituents are provided in combinations and amounts recited in the Summary and Examples. In particular embodiments, the alloy is Ti-Ta, Ti-Mo, Ti-Zr, Ti-Ta-Mo, Ti-Ta-Zr, Ti-Ta-Zr-Mo, Ti-Zr-Mo or Ti 6A1-4V-Ta, Ti 6A1-4V-Mo, Ti 6A1-4V-Zr, Ti 6A1-4V-Ta-Mo, Ti 6A1-4V-Ta-Zr, Ti 6A1-4V-Ta-Zr-Mo, or Ti 6A1-4V-Zr-Mo alloy. In other embodiments, Ti-13Nb-13Zr, Ti-8A1-1Mo-1V, Ti-6A1-2Nb-1 Ta-0.8Mo and Ti-7A1-4Mo one alloyed with Ta, Mo, and/or Zr. In particular embodiments, the alloy is annealed. In particular embodiments, the alloy is formed by alloying CP titanium or Ti-6A1-4V ELI with Ta, Zr and/or Mo. In embodiments, the alloy includes 40 to 70 weight percent tantalum or 25 to 50 weight percent zirconium with CP titanium or Ti-6A1-4V ELI. In embodiments, 5 to 20 weight percent molybdenum is added in place of some of the titanium for added tensile strength without sacrificing MRI compatibility. Suitable alloys include the following:
    CP Titanium alloyed with: Ti—6Al—4V ELI alloyed with:
    43 weight % Ta 43 weight % Ta
    69 weight % Ta 69 weight % Ta
    25 weight % Ta 25 weight % Ta
    49 weight % Zr 49 weight % Zr
    43 weight % Ta + 5% Mo 43 weight % Ta + 5% Mo
    69 weight % Ta + 5% Mo 69 weight % Ta + 5% Mo
    25 weight % Zr + 5% Mo 25 weight % Zr + 5% Mo
    49 weight % Zr + 5% Mo 49 weight % Zr + 5% Mo
    43 weight % Ta + 10% Mo 43 weight % Ta + 10% Mo
    69 weight % Ta + 10% Mo 69 weight % Ta + 10% Mo
    25 weight % Zr + 10% Mo 25 weight % Zr + 10% Mo
    49 weight % Zr + 10% Mo 49 weight % Zr + 10% Mo
    22 weight % Ta + 13% Zr 22 weight % Ta + 13% Zr
    35 weight % Ta + 25% Zr 35 weight % Ta + 25% Zr
    • Manufacture
  • [0035]
    Referring to FIG. 3, a stent is constructed by forming an alloy, forming a tube from the alloy, and then forming the tube into a stent.
  • [0036]
    Referring to FIGS. 4A to 4E, an alloying process is illustrated for forming an ingot or billet of a size and form suitable for stent construction.
  • [0037]
    Referring to FIG. 4A, a base rod 60 and one or more additive rods 62 are provided. For example, the base rod is Ti or a Ti-containing alloy and the additive rod(s) are Ti, Ta, Zr, and/or Mo. The weight of the rods are in proportion to the desired alloy formulation.
  • [0038]
    Referring to FIG. 4B, the base rod is drilled to provide voids 64.
  • [0039]
    Referring to FIG. 4C, additive rods 62 are inserted into the voids 64 of the base rod 60.
  • [0040]
    Referring to FIG. 4D, this assembly is prealloyed by heating and/or mechanically working to cause diffusion alloying between constituents.
  • [0041]
    Referring to FIG. 4E, the assembly is provided with end caps to prevent additive rods 62 from falling out of base rod 60. The assembly is melted and cast once or multiple times in a vacuum are remelt (VAR) furnace, EB melting furnace, VIM furnace, or levitation melting furnace to allow liquid-phase alloying to occur.
  • [0042]
    Referring to FIG. 4F, the alloy (e.g., the alloyed billet is suitable for further processing. The billet can be drawn into tubing or rolled into a sheet for stock stent tubing production. For example an ingot or billet 2.5 inches in diameter by 4 inches long can typically yield at least 1000 feet of coronary stent tubing.
  • [0043]
    The alloying process is particularly advantageous for alloying constituents with large melting temperature differences. In Table IV, the melting temperatures of Ti, Ta, Zr, and Mo are provided.
    TABLE IV
    Melting Temperatures
    Element Melting Temperature, ° C.
    Ti 1668
    Ta 2996
    Zr 1852
    Mo 2610
  • [0044]
    The melting temperature difference between Ti and Zr, and Ta and Mo is over 500° C. The difference between Ti and Zr is over 150° C. In the method of FIGS. 4A et seq., aliquots of constituents of the alloy are intimately contacted, mechanically and/or diffusion alloyed and then melted and cast into ingot. By diffusion or mechanical alloying the aliquots, less overall mixing is required in the melting and casting furnace.
  • [0045]
    In the prealloying step, heating is performed in an inert gas or vacuum, or the outer surfaces of the billet could be coated or canned with a protective metal, such as iron, that could later be chemically dissolved. After drilling and filling or after the diffusion heat treatment, the billet can also be extruded, drawn, or rolled to further consolidate the assembly. The heat treatment or working serves to hold additive material in place within the billet during melting. Also, constituents with high melting points can be essentially encapsulated within, e.g. titanium, minimizing the exposure to any residual air in the casting furnace. For diffusion heating, the assembly can be heated near the melting temperature of the lowest melting temperature constituent and/or the melting temperature of the material of the base rod. For example, for a Ti base rod, the temperature is about 1600° C. or less.
  • [0046]
    In embodiments, additives to the base are made in incremental steps in each of multiple melting and ingot casting operations. For example, to alloy Ti 6A1-4V with 43 weight percent tantalum, in the first melting operation the Ti-6A1 -4V bar holes may be filled with 22 weight percent tantalum. After the first ingot is cast, holes are drilled again and filled with another 22 weight percent tantalum and the melting is repeated. Other sequences and magnitudes of Ta adds are made to reach the final alloy with 43 weight percent Ta. This approach is Ta elemental segregation in the ingot if it is added in smaller amounts in multiple melting and ingot casting steps. In addition, homogenization heat treatments between melts can reduce the amount of elemental diffusion needed. Other difficult to melt alloys can be produced by this method such as Ta-Nb, Nb-Zr, Ti-Nb, and Fe-Pt alloy systems. In other embodiments, the additive can be provided in the form of powder or chips rather than a solid wire or rod. The alloying that occurs in the melting and ingot casting process can be further improved by performing a homogenization (elemental diffusion) heat treatment to the ingots between melting operations. Mechanical alloying melting, casting, and heat treating operations can be performed at commercial sources such as Pittsburgh Materials Technology Inc. (Pittsburgh, Pa.), Applegate Group (Woodcliff Lake, N.J.) or Albany Research Center (Albany, Ore.).
  • [0047]
    The alloy tubing is formed into stent. For example, selected portions can be removed to define bands and struts. The portions can be removed by laser cutting, as described, for example, in U.S. Pat. No. 5,780,807. In certain embodiments, during laser cutting, a liquid carrier, such as a solvent, gas, or an oil, is flowed through the tube. The carrier can prevent drops formed on one portion from re-depositing on another portion, and/or reduce formation of recast material on the tubular member. Other methods of removing portions of tubular member include mechanical machining (e.g., micro-machining), electrical discharge machining (EDM), photoetching (e.g., acid photoetching), and/or chemical etching.
  • [0048]
    The stent can further be finished, e.g., electropolished to a smooth finish, according to conventional methods. In some embodiments, about 0.0001 inch of material can be removed from the interior and/or exterior surfaces by chemical milling and/or electropolishing. The stent can be annealed to refine the mechanical and physical properties of the stent.
  • [0049]
    In use, the stent can be used, e.g., delivered and expanded, using a catheter. Suitable catheter systems are described in, for example, Wang U.S. Pat. No. 5,195,969, and Hamlin U.S. Pat. No. 5,270,086. Suitable stents and stent delivery are also exemplified by the Express, Radius® or Symbio® systems, available from Boston Scientific Scimed, Maple Grove, Minn.
  • [0050]
    The stent can be of any desired shape and size (e.g., coronary stents, aortic stents, peripheral vascular stents, gastrointestinal stents, urology stents, and neurology stents). Depending on the application, the stent can have a diameter of between, for example, 1 mm to 46 mm. In certain embodiments, a coronary stent can have an expanded diameter of from about 2 mm to about 6 mm. In some embodiments, a peripheral stent can have an expanded diameter of from about 5 mm to about 24 mm. In certain embodiments, a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 mm to about 30 mm. In some embodiments, a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm. An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm. Stent 100 can be balloon-expandable, self-expandable, or a combination of both (e.g., U.S. Pat. No. 5,366,504).
  • [0051]
    The stent can also be a part of a stent-graft. In other embodiments, the stent includes and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene. The endoprosthesis can include a releasable therapeutic agent, drug, or a pharmaceutically active compound, such as described in U.S. Pat. No. 5,674,242, U.S. Ser. No. 09/895,415, filed Jul. 2, 2001 and U.S. Ser. No. 10/232,265, filed Aug. 30, 2002. The therapeutic agents, drugs, or pharmaceutically active compounds can include, for example, anti-thrombogenic agents, antioxidants, anti-inflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
  • [0052]
    The methods and the embodiments described above can be used to form medical devices other than stents and stent-grafts. For example, the methods and/or materials can be used to form filters, such as removable thrombus filters described in Kim et al., U.S. Pat. No. 6,146,404; in intravascular filters such as those described in Daniel et al., U.S. Pat. No. 6,171,327; and in vena cava filters such as those described in Soon et al., U.S. Pat. No. 6,342,062. The methods and/or materials can be used to form guidewires, such as a Meier steerable guidewire. The methods and/or materials can be used to form vaso-occlusive devices, e.g., coils, used to treat intravascular aneurysms, as described, e.g., in Bashiri et al., U.S. Pat. No. 6,468,266, and Wallace et al., U.S. Pat, No. 6,280,457. The methods and/or materials can be used to form wire to make catheter reinforcement braid. The methods and/or materials can also be used in surgical instruments, such as forceps, needles, clamps, and scalpels.
  • [0053]
    Further embodiments are provided in the following examples.
  • EXAMPLES Example 1
  • [0054]
    A titanium-tantalum alloy with a mass absorption coefficient of at least 1.96 cm2/g (iron) and as high as 2.86 cm2/g (half of tantalum) is formulated as follows. The atomic mass coefficient for titanium is 1.21 and for tantalum is 5.72.
  • [0055]
    The following equation is used to provide desired radiopacity.
    [Atomic % Ti×1.21]+[atomic % Ta×5.72]=1.96 to 2.86 cm2/g. solving far x: (x)(1.21)+(1−x)(5.72)=1.96 cm2/g or 2.86 cm2/g x=0.83 (83 atomic percent Ti) or 0.63 (63 atomic percent TI) or conversely 17 atomic percent Ta or 37 atomic percent Ta.
  • [0056]
    Conversion of atomic percent to weight percent for the 17 Ta-83 Ti alloy is as follows:
      • In 1023 atoms of Ti-Ta alloy, there are 0.17×1023 atoms of Ta and 0.83×1023 atoms of Ti.
      • 0.17×1023 atoms of Ta/6.02×1023 atoms/mole=0.028 moles of Ta
      • 0.83×1023 atoms of Ti/6.02×1023 atoms/mole=0.138 moles of Ti
      • (0.028 moles Ta)(180.95 grams/mole atomic weight)=5.07 grams of Ta
      • (0.138 moles Ti)(47.88 grams/mole atomic weight)=6.61 grams of Ti
      • 5.07 grams Ta+6.61 grams Ti=11.68 grams of alloy
      • 6.61g Ti/11.68 g=57 weight percent Ti in alloy.
      • 5.07g Ta/11.68 g=43 weight percent Ta in alloy.
  • [0065]
    An alloy of 83 atomic percent Ti and 17 atomic percent Ta (57 weight percent Ti and 43 weight percent Ta) has a calculated mass absorption coefficient equivalent to iron and a radiopacity similar to 316L stainless steel. An alloy of 63 atomic percent Ti and 37 atomic percent Ta (31 weight percent Ti and 69 weight percent Ta) has a calculated mass absorption coefficient equivalent to one-half of tantalum. The alloy constituents have magnetic susceptibility less than 3.5×10−3 and are soluble in each other. The tantalum-titanium binary phase diagram (ASM Handbook, Volume 3 Alloy Phase Diagrams, ASM International, 1992, p. 2.374) indicates a 43 to 69 weight percent tantalum to be soluble in titanium as a solid solution two-phase (alpha and beta) material at room temperature. The tantalum-titanium binary phase diagram also indicates that the alloys with 43 to 69 percent tantalum concentration have alpha and beta phase microstructures. No brittle phases are evident in the phase diagram.
  • Example 2
  • [0066]
    A titanium-molybdenum alloy with a mass absorption coefficient of at least 1.96 cm2/g (iron) and as high as 2.86 cm2/g (halfoftantalum) is formulated as follows.
  • [0067]
    The following equation is used to determine desired radiopacity.
    [Atomic % Ti×1.21]+[atomic % Mo×7.04]=1.96 to 2.86 cm2/g. (x) (1.21)+(1−x)(7.04)=1.96 cm2/g or 2.86 cm2/g x=0.87 (87 atomic percent Ti) or 0.72 (72 atomic percent Ti) or conversely 13 atomic percent Mo or 28 atomic percent Mo.
  • [0068]
    Conversion of atomic percent to weight percent for the 13 Mo-87 Ti alloy:
      • In 1023 atoms of Ti-Mo alloy, there are 0.13×1023 atoms of Mo and 0.87×1023 atoms of Ti.
      • 0.13×1023 atoms of Mo/6.02×1023 atoms/mole=0.022 moles of Mo
      • 0.87×1023 atoms of Ti/6.02×1023 atoms/mole=0.145 moles of Ti
      • (0.022 moles Mo) (95.94 grams/mole atomic weight)=2.11 grams of Mo
      • (0.145 moles Ti) 47.88 grams/mole atomic weight)=6.94 grams of Ti
      • 2.11 grams Mo+6.94 grams Ti=9.05 grams of alloy
      • 6.94g Ti/9.05 g=77 weight percent Ti in alloy.
      • 2.11 g Mo/9.05 g=23 weight percent Mo in alloy.
  • [0077]
    An alloy of 87 atomic percent Ti and 13 atomic percent mo (77 weight percent Ti and 23 weight percent Mo) has a calculated mass absorption coefficient equivalent to iron and a radiopacity similar to 316L stainless steel. An alloy of 72 atomic percent Ti and 28 atomic percent Mo (56 weight percent Ti and 44 weight percent Mo) has a calculated mass absorption coefficient equivalent to one-half of tantalum and therefore has half the radiopacity of tantalum. The alloy constituents have magnetic susceptibility less than 3.5×10−3 and that are soluble in each other. The molybdenum titanium binary phase diagram indicates (ASM Handbook, Volume 3 Alloy Phase Diagrams, ASM International, 1992, p.2.296) 23 to 44 weight percent molybdenum to be soluble in titanium as a solid solution single (beta) or two-phase (alpha and beta) material at room temperature. The molybdenum-titanium binary phase diagram also indicates that alloys with 23 to 44 percent molybdenum concentration will have beta or beta plus alpha phase microstructures which are common in commercialized titanium engineering alloys such as Ti-6A1-4V. Cooling through the temperature range of about 850 to 695° C. can be performed rapidly (e.g., by argon gas, air cool, or liquid quenchant) to avoid precipitation of significant amounts of alpha-prime, alpha-double prime, or omega phases.
  • Example 3
  • [0078]
    A method for making an alloy of Ti-6A1-4V ELI with 43 weight percent Ta follows.
  • [0079]
    Procure a 3″ diameter round bar of Ti-6A1-4V ELI (such as form Titanium Industries, Inc. in Morristown, N.J.) and cut to 5.5 inches long. Procure 0.5″ diameter tantalum rod (such as from Rembar, Dobbs Ferry, N.Y.) and cut into lengths of 3.25″. Drill eight holes into the titanium bar that are 0.55/0.6″ diameter and 4.5″ deep. Put the eight 3.25″ long pieces of 0.5″ diameter tantalum rod into the holes. Heat the assembly in a vacuum furnace at 1400° C. for 8 hours and vacuum cool. Gas tungsten arc weld (GTAW or TIG) the assembly with the hole-end up to the vacuum arc remelt (VAR) electrode holder. Vacuum arc remelt the assembly and cast an ingot. Heat the ingot in a vacuum furnace at 1400° C. for 8 hours and vacuum cool. Repeat the VAR and heat treatment once ore or multiple times. Machine the ingot into a 2.5″ diameter×4″ long billet. Convert billet to annealed seamless tent tubing.
  • Example 4
  • [0080]
    Arc melted Ti-Ta alloy button ingots were prepared. Two ingots were melted from a 50-50 mixture (by weight) of Ti-6A1-4V and tantalum rods. One ingot was melted from a 50-50 mixture (by weight) of pure titanium and tantalum rods. Cold rolling and annealing of the ingots were used to form strips for mechanical and physical property testing.
  • [0081]
    The ingots were prepared from the following rods and charge materials procured from Goodfellow Corporation, Berwyn, Pa.
    TABLE V
    Rods
    Material Traceability
    Ti—6Al—4V Goodfellow LS251817JV; TI017910/1, 5 mm dia ×
    rods 200 mm long rods, 10 pcs, 174 g, annealed
    Ta rods Goodfellow LS251817JV, TA007920/8, 99.9% pure,
    2 mm dia × 200 mm long rods, 5 pcs, 53.2 g, annealed
    Ti rods Goodfellow LS251817JV, TI007910/12, 2 mm dia ×
    100 mm long rods, 20 pcs, 28.5 g, 99.6% pure, annealed
  • [0082]
    TABLE VI
    Arc Melter Charge Materials
    Ti—6Al—4V, # of Ingot mass,
    Ingot # grams Ti, g Ta, g melt cycles g
    2&3 26.0 25.8 3 51.7
    1 27.6 26.5 3 53.9
  • [0083]
    The rods were cut into lengths of 1-2″, cleaned in acetone, and weighed on a digital scale. The rods were divided up by weight into two groups for melting. The raw materials were melted in an arc melter (Model MRF ABJ-900, Materials Research Furnaces, Inc., Suncook, N.H.). The arc melter was operated at 350-400 amps. Three melt cycles were performed for each alloy.
  • [0084]
    Referring to FIG. 5, a photomacrograph shows the three ingots after arc melting. The ingot on the left is the Ti-50Ta alloy. The other two ingots are the 50 (Ti-6A1-4V)-50Ta alloy. After melting, each ingot was struck ten times with a hammer to see if it would crack or fracture. All three of the ingots withstood the hammer test without cracking or fracturing and the ingot deformed when hit. This test was performed as an assessment of the formability of the material. Cracking can indicate that the alloy is too brittle for cold rolling.
  • [0085]
    Three 0.20-0.25″ thick bars were used as a starting stock for cold rolling. The machined dimensions of the rolling blanks are listed in the following table.
    TABLE VII
    Dimensions of Rolling Blanks
    Bar # Length, inches Width, inches Thickness, inches
    1 (Ti—Ta) 3.06 0.57 0.23
    2 (Ti64—Ta) 2.17 0.57 0.23
    3 (Ti64—Ta) 1.12. 0.49 0.24
  • [0086]
    The machined bars were cold rolled to a total reduction in thickness of 50%. The dimensions after cold rolling are listed in the following table.
    TABLE VIII
    Dimensions after 1st Cold Rolling
    Bar # Length, inches Thickness, inches
    1 (Ti—Ta) 4.7 0.10
    2 (Ti64—Ta) 3.2 0.10
    3 (Ti64—Ta) 1.7 0.10
  • [0087]
    The cold rolled strips were annealed in the a vacuum heat treat furnace at 1200° C. for 60 minutes in vacuum followed by a vacuum cool. The purpose of this heat treatment was to continue to homogenize the alloy, recrystallize the cold worked microstructure, and soften the material to allow for further cold rolling. Referring to FIG. 6, fine fissures were observed on the surface of the strips. Strip #3 had small edge cracks along the length. None of these flaws were judged to be severe enough to impair further cold rolling.
  • [0088]
    The three strips were cold rolled to a total reduction in thickness of −50%. The dimensions of the rolled strips are listed in Table IX.
    TABLE IX
    Dimension of Strips After Second Cold Rolling
    Bar # Length, inches Width, inches Thickness, inches
    1 (Ti—Ta) 7.75 0.75 0.058
    2 (Ti64—Ta) 4.87 0.81 0.058
    3 (Ti64—Ta) 3.00 0.62 0.058
  • [0089]
    Referring to FIG. 7, the surface and edges of the strips were examined without magnification. Strip #1 had fine edge cracks. Strip #2 had no cracks. Strip #3 had edge cracks.
  • [0090]
    The cold rolled strips were annealed in the vacuum heat treat furnace at 1000° C. for 30 minutes in vacuum followed by a vacuum cool. The purpose of this heat treatment was to recrystallize the cold worked microstructure and soften the material to allow further cold rolling. The strips were cold rolled to 0.025″ thickness. The dimensions are given in Table X.
    TABLE X
    Dimension of Strips After Third Cold Rolling Campaign
    Bar # Length, inches Width, inches Thickness, inches
    1 (Ti—Ta) 9 and 8 079 0.025
    2 (Ti64—Ta) 10 0.88 0.025
    3 (Ti64—Ta)  6 0.65 0.025
  • [0091]
    Referring to FIG. 8, Strips #1 and #3 had many small edge cracks. Strip #2 did not have edge cracks.
  • [0092]
    The strips were beta solution treated in a vacuum heat treat furnace at 850° C. for 30 minutes and cooled in vacuum. The strips were submitted for metallography. The strips were subjected to tensile specimen machining and testing (Metcut Research Associates, Inc. (Cincinnati, Ohio)). The tensile results were 85-115 ksi UTS, 65-105 YS, and 5-25% elongation.
  • [0093]
    Ti-6A1-4V, pure titanium, and tantalum materials had been melted in powder metal form. Sometimes the ingots did not have sufficient formability to allow cold rolling to a final reduction in thickness of 50%. The large surface area of fine powder metal may allow for significant contamination to be carried into the ingot thereby reducing the ductility of the alloy. In this experiment, solid rods were used instead of powder metal for the furnace charges. The smaller surface area of the rods (relative to the powder) should result in better ingot ductility.
  • [0094]
    All publications, applications, references, patents referred to in this application are herein incorporated by reference in their entirety.
  • [0095]
    Other embodiments are within the claims.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3161503 *Sep 27, 1961Dec 15, 1964Titanium Metals CorpCorrosion resistant alloy
US4040129 *Feb 24, 1975Aug 9, 1977Institut Dr. Ing. Reinhard Straumann AgSurgical implant and alloy for use in making an implant
US5047030 *Jun 20, 1990Sep 10, 1991Klaus DraenertSuction drainage-bone screw
US5169597 *Jan 28, 1991Dec 8, 1992Davidson James ABiocompatible low modulus titanium alloy for medical implants
US5195969 *Apr 26, 1991Mar 23, 1993Boston Scientific CorporationCo-extruded medical balloons and catheter using such balloons
US5270086 *Jul 9, 1991Dec 14, 1993Schneider (Usa) Inc.Multilayer extrusion of angioplasty balloons
US5366504 *Jul 13, 1992Nov 22, 1994Boston Scientific CorporationTubular medical prosthesis
US5383928 *Aug 19, 1993Jan 24, 1995Emory UniversityStent sheath for local drug delivery
US5545227 *Jun 20, 1994Aug 13, 1996Smith & Nephew Richards, Inc.Biocompatible low modulus medical implants
US5643312 *Feb 25, 1994Jul 1, 1997Fischell RobertStent having a multiplicity of closed circular structures
US5653727 *Jan 18, 1996Aug 5, 1997Medtronic, Inc.Intravascular stent
US5685306 *Jun 6, 1995Nov 11, 1997Smith & Nephew, Inc.Flexible, biocompatible, metal alloy catheter
US5690670 *Jun 6, 1995Nov 25, 1997Davidson; James A.Stents of enhanced biocompatibility and hemocompatibility
US5728158 *Jan 14, 1997Mar 17, 1998Advanced Cardiovascular Systems, Inc.Expandable stents
US5780807 *Jan 15, 1997Jul 14, 1998Advanced Cardiovascular Systems, Inc.Method and apparatus for direct laser cutting of metal stents
US5888201 *Jun 13, 1997Mar 30, 1999Schneider (Usa) IncTitanium alloy self-expanding stent
US5954724 *Mar 27, 1997Sep 21, 1999Davidson; James A.Titanium molybdenum hafnium alloys for medical implants and devices
US5972027 *Sep 30, 1997Oct 26, 1999Scimed Life Systems, IncPorous stent drug delivery system
US6027528 *Mar 30, 1998Feb 22, 2000Cordis CorporationComposite material endoprosthesis
US6146404 *Sep 3, 1999Nov 14, 2000Scimed Life Systems, Inc.Removable thrombus filter
US6171327 *Feb 24, 1999Jan 9, 2001Scimed Life Systems, Inc.Intravascular filter and method
US6200685 *Feb 2, 1999Mar 13, 2001James A. DavidsonTitanium molybdenum hafnium alloy
US6258182 *Mar 5, 1999Jul 10, 2001Memry CorporationPseudoelastic β titanium alloy and uses therefor
US6280457 *Jun 4, 1999Aug 28, 2001Scimed Life Systems, Inc.Polymer covered vaso-occlusive devices and methods of producing such devices
US6342062 *Sep 23, 1999Jan 29, 2002Scimed Life Systems, Inc.Retrieval devices for vena cava filter
US6375458 *May 17, 1999Apr 23, 2002Memry CorporationMedical instruments and devices and parts thereof using shape memory alloys
US6409852 *Jan 7, 1999Jun 25, 2002Jiin-Huey ChernBiocompatible low modulus titanium alloy for medical implant
US6468266 *Aug 22, 2000Oct 22, 2002Scimed Life Systems, Inc.Fast detaching electrically isolated implant
US20030003220 *Jul 2, 2001Jan 2, 2003Sheng-Ping ZhongCoating a medical appliance with a bubble jet printing head
US20030185895 *Aug 30, 2002Oct 2, 2003Janel LanphereDrug delivery particle
US20040143317 *Jan 17, 2003Jul 22, 2004Stinson Jonathan S.Medical devices
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7641983Apr 4, 2005Jan 5, 2010Boston Scientific Scimed, Inc.Medical devices including composites
US7778684Aug 8, 2005Aug 17, 2010Boston Scientific Scimed, Inc.MRI resonator system with stent implant
US7780798Mar 29, 2007Aug 24, 2010Boston Scientific Scimed, Inc.Medical devices including hardened alloys
US7887579 *Sep 12, 2007Feb 15, 2011Merit Medical Systems, Inc.Active stent
US7931683Jul 27, 2007Apr 26, 2011Boston Scientific Scimed, Inc.Articles having ceramic coated surfaces
US7938855Nov 2, 2007May 10, 2011Boston Scientific Scimed, Inc.Deformable underlayer for stent
US7942926Jul 11, 2007May 17, 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US7955382Sep 14, 2007Jun 7, 2011Boston Scientific Scimed, Inc.Endoprosthesis with adjustable surface features
US7976915May 23, 2007Jul 12, 2011Boston Scientific Scimed, Inc.Endoprosthesis with select ceramic morphology
US7981150Sep 24, 2007Jul 19, 2011Boston Scientific Scimed, Inc.Endoprosthesis with coatings
US7985252Jul 30, 2008Jul 26, 2011Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US7998192May 9, 2008Aug 16, 2011Boston Scientific Scimed, Inc.Endoprostheses
US8002821Sep 13, 2007Aug 23, 2011Boston Scientific Scimed, Inc.Bioerodible metallic ENDOPROSTHESES
US8002823Jul 11, 2007Aug 23, 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US8029554Nov 2, 2007Oct 4, 2011Boston Scientific Scimed, Inc.Stent with embedded material
US8048150Apr 12, 2006Nov 1, 2011Boston Scientific Scimed, Inc.Endoprosthesis having a fiber meshwork disposed thereon
US8052743Aug 2, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis with three-dimensional disintegration control
US8052744Sep 13, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US8052745Sep 13, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis
US8057534Sep 14, 2007Nov 15, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8066763May 11, 2010Nov 29, 2011Boston Scientific Scimed, Inc.Drug-releasing stent with ceramic-containing layer
US8067054Apr 5, 2007Nov 29, 2011Boston Scientific Scimed, Inc.Stents with ceramic drug reservoir layer and methods of making and using the same
US8070797Feb 27, 2008Dec 6, 2011Boston Scientific Scimed, Inc.Medical device with a porous surface for delivery of a therapeutic agent
US8071155May 5, 2005Dec 6, 2011Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US8071156Mar 4, 2009Dec 6, 2011Boston Scientific Scimed, Inc.Endoprostheses
US8080055Dec 27, 2007Dec 20, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8089029Feb 1, 2006Jan 3, 2012Boston Scientific Scimed, Inc.Bioabsorbable metal medical device and method of manufacture
US8114153Sep 5, 2008Feb 14, 2012Boston Scientific Scimed, Inc.Endoprostheses
US8128689Sep 14, 2007Mar 6, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis with biostable inorganic layers
US8187620Mar 27, 2006May 29, 2012Boston Scientific Scimed, Inc.Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8205317 *Jul 16, 2007Jun 26, 2012Medtronic Vascular, Inc.Method of manufacturing a controlled porosity stent
US8216632Nov 2, 2007Jul 10, 2012Boston Scientific Scimed, Inc.Endoprosthesis coating
US8221822Jul 30, 2008Jul 17, 2012Boston Scientific Scimed, Inc.Medical device coating by laser cladding
US8231980Dec 3, 2009Jul 31, 2012Boston Scientific Scimed, Inc.Medical implants including iridium oxide
US8236046Jun 10, 2008Aug 7, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US8267992Mar 2, 2010Sep 18, 2012Boston Scientific Scimed, Inc.Self-buffering medical implants
US8287937Apr 24, 2009Oct 16, 2012Boston Scientific Scimed, Inc.Endoprosthese
US8303643May 21, 2010Nov 6, 2012Remon Medical Technologies Ltd.Method and device for electrochemical formation of therapeutic species in vivo
US8340759Apr 22, 2011Dec 25, 2012Medtronic, Inc.Large-pitch coil configurations for a medical device
US8353949Sep 10, 2007Jan 15, 2013Boston Scientific Scimed, Inc.Medical devices with drug-eluting coating
US8382824Oct 3, 2008Feb 26, 2013Boston Scientific Scimed, Inc.Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149Feb 27, 2008Apr 30, 2013Boston Scientific Scimed, Inc.Coated medical devices for abluminal drug delivery
US8449603Jun 17, 2009May 28, 2013Boston Scientific Scimed, Inc.Endoprosthesis coating
US8574615May 25, 2010Nov 5, 2013Boston Scientific Scimed, Inc.Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8639352Apr 6, 2009Jan 28, 2014Medtronic, Inc.Wire configuration and method of making for an implantable medical apparatus
US8660662Apr 22, 2011Feb 25, 2014Medtronic, Inc.Low impedance, low modulus wire configurations for a medical device
US8668732Mar 22, 2011Mar 11, 2014Boston Scientific Scimed, Inc.Surface treated bioerodible metal endoprostheses
US8715339Nov 21, 2011May 6, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8758429Sep 6, 2012Jun 24, 2014Micell Technologies, Inc.Polymer coatings containing drug powder of controlled morphology
US8771343Jun 15, 2007Jul 8, 2014Boston Scientific Scimed, Inc.Medical devices with selective titanium oxide coatings
US8790392May 25, 2011Jul 29, 2014Boston Scientific Scimed, Inc.Endoprosthesis coating
US8795762Mar 26, 2010Aug 5, 2014Battelle Memorial InstituteSystem and method for enhanced electrostatic deposition and surface coatings
US8808726Sep 14, 2007Aug 19, 2014Boston Scientific Scimed. Inc.Bioerodible endoprostheses and methods of making the same
US8815273Jul 27, 2007Aug 26, 2014Boston Scientific Scimed, Inc.Drug eluting medical devices having porous layers
US8815275Jun 28, 2006Aug 26, 2014Boston Scientific Scimed, Inc.Coatings for medical devices comprising a therapeutic agent and a metallic material
US8834560Mar 18, 2011Sep 16, 2014Boston Scientific Scimed, Inc.Endoprosthesis
US8834913Dec 28, 2009Sep 16, 2014Battelle Memorial InstituteMedical implants and methods of making medical implants
US8840660Jan 5, 2006Sep 23, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8852625Apr 26, 2007Oct 7, 2014Micell Technologies, Inc.Coatings containing multiple drugs
US8895099Mar 18, 2011Nov 25, 2014Boston Scientific Scimed, Inc.Endoprosthesis
US8900292Oct 6, 2009Dec 2, 2014Boston Scientific Scimed, Inc.Coating for medical device having increased surface area
US8900651Dec 4, 2008Dec 2, 2014Micell Technologies, Inc.Polymer films for medical device coating
US8920490May 12, 2011Dec 30, 2014Boston Scientific Scimed, Inc.Endoprostheses
US8920491Apr 17, 2009Dec 30, 2014Boston Scientific Scimed, Inc.Medical devices having a coating of inorganic material
US8932346Apr 23, 2009Jan 13, 2015Boston Scientific Scimed, Inc.Medical devices having inorganic particle layers
US9011516Jun 15, 2007Apr 21, 2015Boston Scientific Scimed, Inc.Medical devices including composites
US9034456Jul 19, 2007May 19, 2015Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US9078777Jul 9, 2008Jul 14, 2015Boston Scientific Scimed, Inc.Stent with non-round cross-section in an unexpanded state
US20050278929 *Jun 16, 2004Dec 22, 2005National Taipei University TechnologyProcess of manufacturing stent with therapeutic function in the human body
US20060097242 *Nov 9, 2005May 11, 2006Mitsubishi Denki Kabushiki KaishaSemiconductor light-emitting device
US20060122694 *Dec 3, 2004Jun 8, 2006Stinson Jonathan SMedical devices and methods of making the same
US20060222844 *Apr 4, 2005Oct 5, 2006Stinson Jonathan SMedical devices including composites
US20060251794 *May 5, 2005Nov 9, 2006Torsten ScheuermannMedical devices and methods of making the same
US20060259126 *May 5, 2005Nov 16, 2006Jason LenzMedical devices and methods of making the same
US20060276875 *May 27, 2005Dec 7, 2006Stinson Jonathan SMedical devices
US20070009564 *Jun 22, 2005Jan 11, 2007Mcclain James BDrug/polymer composite materials and methods of making the same
US20070032861 *Aug 8, 2005Feb 8, 2007Boston Scientific Scimed, Inc.MRI resonator system with stent implant
US20070032862 *Mar 22, 2006Feb 8, 2007Jan WeberMedical devices
US20070131318 *Nov 9, 2006Jun 14, 2007Accellent, Inc.Medical alloys with a non-alloyed dispersion and methods of making same
US20070239256 *Mar 22, 2006Oct 11, 2007Jan WeberMedical devices having electrical circuits with multilayer regions
US20080069858 *Aug 10, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Medical devices having biodegradable polymeric regions with overlying hard, thin layers
US20080071344 *Sep 5, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Medical device with porous surface
US20080071351 *Sep 14, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Endoprosthesis with adjustable surface features
US20080071352 *Sep 14, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Bioerodible endoprosthesis with biostable inorganic layers
US20080071355 *Sep 10, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Medical Devices with Drug-Eluting Coating
US20080095919 *Oct 23, 2007Apr 24, 2008Mcclain James BHolder For Electrically Charging A Substrate During Coating
US20080097577 *Sep 18, 2007Apr 24, 2008Boston Scientific Scimed, Inc.Medical device hydrogen surface treatment by electrochemical reduction
US20080131479 *Aug 2, 2007Jun 5, 2008Jan WeberEndoprosthesis with three-dimensional disintegration control
US20080132998 *Sep 12, 2007Jun 5, 2008Alveolus, Inc.Active stent
US20080147177 *Sep 24, 2007Jun 19, 2008Torsten ScheuermannEndoprosthesis with coatings
US20080160259 *Jul 19, 2007Jul 3, 2008Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US20080161900 *Jun 15, 2007Jul 3, 2008Boston Scientific Scimed, Inc.Medical devices including composites
US20080195194 *Feb 11, 2008Aug 14, 2008Abbott Cardiovascular Systems Inc.Mri compatible, radiopaque alloys for use in medical devices
US20090024199 *Jul 16, 2007Jan 22, 2009Medtronic Vascular, Inc.Controlled Porosity Stent
US20090118814 *Nov 2, 2007May 7, 2009Boston Scientific Scimed, Inc.Endoprosthesis coating
US20090118821 *Nov 2, 2007May 7, 2009Boston Scientific Scimed, Inc.Endoprosthesis with porous reservoir and non-polymer diffusion layer
US20090149942 *Jul 17, 2008Jun 11, 2009Boston Scientific Scimed, Inc.Endoprosthesis having a non-fouling surface
US20090186069 *Apr 26, 2007Jul 23, 2009Micell Technologies, Inc.Coatings Containing Multiple Drugs
US20090214373 *May 7, 2009Aug 27, 2009Boston Scientific Scimed, Inc.Medical Devices
US20090285714 *Jan 7, 2009Nov 19, 2009Pulse Technologies, Inc.Implantable medical Devices Composed of a Radiopaque Alloy and Method of Making the Alloy
US20090292351 *Nov 26, 2009Micell Technologies, Inc.Stents having bioabsorbable layers
US20090299468 *May 20, 2009Dec 3, 2009Boston Scientific Scimed, Inc.Endoprosthesis coating
US20090319032 *Jun 17, 2009Dec 24, 2009Boston Scientific Scimed, IncEndoprosthesis coating
US20100010620 *Jul 9, 2008Jan 14, 2010Boston Scientific Scimed, Inc.Stent
US20100015200 *Jul 16, 2009Jan 21, 2010Micell Technologies, Inc.Drug Delivery Medical Device
US20100057188 *Mar 4, 2010Boston Scientific Scimed, Inc.Endoprostheses with porous regions and non-polymeric coating
US20100063580 *Jan 8, 2008Mar 11, 2010Mcclain James BStents having biodegradable layers
US20100063584 *Sep 5, 2008Mar 11, 2010Boston Scientific Scimed, Inc.Endoprostheses
US20100211164 *Apr 17, 2008Aug 19, 2010Mcclain James BStents having biodegradable layers
US20100239635 *Sep 23, 2010Micell Technologies, Inc.Drug delivery medical device
US20100241220 *Sep 23, 2010Mcclain James BPeripheral Stents Having Layers
US20100256718 *Apr 6, 2009Oct 7, 2010Medtronic, Inc.Wire Configuration and Method of Making for an Implantable Medical Apparatus
US20100256748 *Mar 31, 2010Oct 7, 2010Micell Technologies, Inc.Coated stents
US20100272778 *Apr 16, 2010Oct 28, 2010Micell Technologies, Inc.Stents having controlled elution
US20100298928 *Oct 17, 2008Nov 25, 2010Micell Technologies, Inc.Drug Coated Stents
US20110022162 *Jul 23, 2009Jan 27, 2011Boston Scientific Scimed, Inc.Endoprostheses
US20110159069 *Dec 28, 2009Jun 30, 2011Shaw Wendy JMedical Implants and Methods of Making Medical Implants
US20110190864 *Aug 4, 2011Micell Technologies, Inc.Stent and stent delivery system with improved deliverability
US20110224783 *Sep 15, 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US20110238149 *Sep 29, 2011Boston Scientific Scimed, Inc.Endoprosthesis
US20110238153 *Sep 29, 2011Boston Scientific Scimed, Inc.Endoprostheses
US20110238161 *Sep 29, 2011Battelle Memorial InstituteSystem and method for enhanced electrostatic deposition and surface coatings
US20150182324 *Oct 8, 2014Jul 2, 2015Keystone Heart Ltd.Implant device particularly useful for implantation in the intravascular system for diverting emboli
WO2008100852A2 *Feb 11, 2008Aug 21, 2008Abbott Cardiovascular SystemsMri compatible, radiopaque alloys for use in medical devices
WO2009142780A1 *Jan 15, 2009Nov 26, 2009Pulse Technolgies, Inc.Implantable medical devices composed of a radiopaque alloy and method making the alloy
Classifications
U.S. Classification623/1.11, 623/1.15
International ClassificationA61L27/06, A61F2/00, C22C14/00, A61F2/06, A61L31/02
Cooperative ClassificationA61F2310/00131, C22C14/00, A61F2310/00089, A61F2310/00095, A61F2240/001, A61F2310/00101, A61L31/022, A61F2310/00023
European ClassificationA61L31/02B, C22C14/00
Legal Events
DateCodeEventDescription
Sep 26, 2003ASAssignment
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STINSON, JONATHAN S.;REEL/FRAME:014555/0763
Effective date: 20030922
Nov 6, 2006ASAssignment
Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018505/0868
Effective date: 20050101